Villers-lès-Nancy, 28 March 2025 - 6:00 p.m.(CET) PRESS RELEASE 2024 annual results Full-year results adversely affected by difficult economic conditions in H1 combined with continuing investment efforts: Revenue: €216.8m (-1.4%)Current Operating Income: €45.1m (-19.2%) Net profit attributable to Group shareholders: €36.2m (-23.0%) At the same time, profit margins remained high, and even improved over the year: Current operating income / Revenue: 20.8% on a reported basis (H1: 19.3% and H2: 22.3%)Solid balance sheet structure: financial surplus remains strong at €79.5mAnnual dividend proposal: €1.25 per share 2025 outlook: Return to revenue growth of close to 10% by the end of 2025Deployment of new solutions integrating artificial intelligenceNew cloud solutions generating recurring revenuesStrategy of external growth in France and Europe maintained 2024 RESULTS (€m) 2023Reported basis 2024Reported basis Change / Reported basis of which External growth Revenue 219.7 216.8 -3.0 -1.4% 7.2 Current Operating Income (COI) 55.8 45.1 -10.7 -19.2% 0.1 Net Profit 48.9 37.8 -11.1 -22.7% Net Profit attributable to the Group 47.0 36.2 -10.8 -23.0% On 28 March 2025, the Board of Directors of EQUASENS, chaired by Thierry CHAPUSOT, examined and approved the financial statements for the year ended 31 December 2024 in the presence of the Statutory Auditors and Sustainability Auditor.
The auditors' report will be issued after the management report has been reviewed and the procedures for filing the annual report have been completed.2024 COI (€m) / Division 2023Reported basis 2024Reported basis Change / Reported basis of whichExternal growth Pharmagest 36.7 30.7 -6.0 -16.4% 0.2 Axigate Link 10.4 10.2 -0.2 - 2.3% e-Connect 6.7 4.8 -1.9 -28.0% Medical Solutions 2.2 0.2 -2.0 -92.0% -0.1 Fintech -0.2 -0.8 -0.6 - Current Operating Income 55.8 45.1 -10.7 -19.2% 0.1 2024 highlights January: Acquisition of a 70% majority stake in DIGIPHARMACIE, an expert in digitisation and management of pharmacy supplier invoices.
Detailed Analysis by Division PHARMAGEST Division: a contraction in earnings reflecting lower like-for-like sales and investments to strengthen teams in Europe (COI/Sales: 18.8% in 2024 and 20.4% for H2 alone) The decline in the Division's operating income was mainly attributable to the unfavourable economic climate in the first half of the year, which led to a sharp drop in sales in France in the configuration and hardware segment.
The story "Equasens: 2024 annual results" has 1041 words across 35 sentences, which will take approximately 5 - 9 minutes for the average person to read.
Which news outlet covered this story?
The story "Equasens: 2024 annual results" was covered 4 days ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 51 news stories per day.
It's most recent story was published 14 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
